CRITICAL PATH INSTITUTE: Form 990, tax year 2017
View the entire original 990 at ProPublica ↗
- Organization
- CRITICAL PATH INSTITUTE (EIN 20-1991334)
- Tax period
- 2017-07-01 to 2018-06-30
- Filed
- 2019-02-27
- IRS object ID
- 201900589349301615
- Schema version
- 2017v2.3
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule C
- Schedule D
- Schedule F
- Schedule I
- Schedule J
- Schedule O
- Schedule R
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2019-02-27T20:09:24-06:00 | ReturnTs |
| Tax Period End | 2018-06-30 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 860683059 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | BEACHFLEISCHMAN PC | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1985 E RIVER ROAD SUITE 201 | AddressLine1Txt |
| City | TUCSON | CityNm |
| State Abbreviation | AZ | StateAbbreviationCd |
| ZIP | 85718 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2017-07-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 201991334 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | CRITICAL PATH INSTITUTE | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | CRIT | BusinessNameControlTxt |
| Phone | 5205473440 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1730 EAST RIVER ROAD NO 200 | AddressLine1Txt |
| City | TUCSON | CityNm |
| State Abbreviation | AZ | StateAbbreviationCd |
| ZIP | 857185898 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | STEVEN BROADBENT MBA | PersonNm |
| Person Title | COO | PersonTitleTxt |
| Phone | 5205473440 | PhoneNum |
| Signature | 2019-02-14 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | KAREN K MCCLOSKEY CPA | PreparerPersonNm |
| PTIN | P00099644 | PTIN |
| Phone | 5203214600 | PhoneNum |
| Preparation | 2019-02-14 | PreparationDt |
Filing Security Information FilingSecurityInformation
IP Address IPAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| I Pv4 Address | 64.128.200.66 | IPv4AddressTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| IP | 2019-02-14 | IPDt |
| IP Tm | 15:48:27 | IPTm |
| IP Timezone | US | IPTimezoneCd |
| Filing License Type | P | FilingLicenseTypeCd |
| At Submission Creation Device Id | 100786DC4CA6AC734CEB2D953EA696EF9CD62243 | AtSubmissionCreationDeviceId |
| At Submission Filing Device Id | 8D176FDB9A9846D98182556421F389029B96F31F | AtSubmissionFilingDeviceId |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2017 | TaxYr |
| Build TS | 2019-02-21 02:37:17Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | MARTHA BRUMFIELD PHD | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1730 EAST RIVER ROAD NO 200 | AddressLine1Txt |
| City | TUCSON | CityNm |
| State Abbreviation | AZ | StateAbbreviationCd |
| ZIP | 857185898 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $15,267,826 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.C-PATH.ORG | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 2004 | FormationYr |
| Legal Domicile State | AZ | LegalDomicileStateCd |
| Activity Or Mission | CREATE AND MANAGE INTERNATIONAL COLLABORATIONS AND DEVELOP NOVEL TOOLS, ENABLING THE FASTER DEVELOPMENT OF SAFER MEDICAL PRODUCTS. | ActivityOrMissionDesc |
| Voting Members Governing Body | 15 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 14 | VotingMembersIndependentCnt |
| Total Employee | 80 | TotalEmployeeCnt |
| Total Volunteers | 13 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $10,085,049 | PYContributionsGrantsAmt |
| CY Contributions Grants | $10,019,550 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $5,531,847 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $5,164,609 | CYProgramServiceRevenueAmt |
| PY Investment Income | $50,971 | PYInvestmentIncomeAmt |
| CY Investment Income | $83,667 | CYInvestmentIncomeAmt |
| PY Other Revenue | $2,500 | PYOtherRevenueAmt |
| CY Other Revenue | $0 | CYOtherRevenueAmt |
| PY Total Revenue | $15,670,367 | PYTotalRevenueAmt |
| CY Total Revenue | $15,267,826 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $1,853,946 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $1,359,100 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $7,188,245 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $8,046,940 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $0 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $0 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $6,113,896 | PYOtherExpensesAmt |
| CY Other Expenses | $5,105,672 | CYOtherExpensesAmt |
| PY Total Expenses | $15,156,087 | PYTotalExpensesAmt |
| CY Total Expenses | $14,511,712 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | $514,280 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | $756,114 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $16,508,211 | TotalAssetsBOYAmt |
| Total Assets EOY | $14,421,996 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $10,541,940 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $7,699,611 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $5,966,271 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $6,722,385 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | THE CRITICAL PATH INSTITUTE IS A CATALYST IN THE DEVELOPMENT OF NEW APPROACHES THAT ADVANCE MEDICAL INNOVATION AND REGULATORY SCIENCE. THIS IS ACHIEVED BY LEADING TEAMS THAT SHARE DATA, KNOWLEDGE AND EXPERTISE RESULTING IN SOUND, CONSENSUS BASED SCIENCE. | MissionDesc |
| Significant New Program Srvc | 0 | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $10,965,542 | ExpenseAmt |
| Grant | $1,359,100 | GrantAmt |
| Revenue | $5,164,609 | RevenueAmt |
| Desc | SEE SCHEDULE O | Desc |
| Total Program Service Expenses | $10,965,542 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (1) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (1) | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Lobbying Activities | Yes (1) | LobbyingActivitiesInd |
| Subject To Proxy Tax | 0 | SubjectToProxyTaxInd |
| Donor Advised Fund | 0 | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | 0 | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Temp Or Permanent Endowments | 0 | TempOrPermanentEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | 0 | ReportOtherAssetsInd |
| Report Other Liabilities | 0 | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | Yes (1) | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | Yes (1) | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | 0 | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | 0 | ForeignOfficeInd |
| Foreign Activities | Yes (1) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (1) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividualsInd |
| Professional Fundraising | 0 | ProfessionalFundraisingInd |
| Fundraising Activities | 0 | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | Yes (1) | GrantsToOrganizationsInd |
| Grants To Individuals | 0 | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | 0 | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | 0 | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | 0 | PYExcessBenefitTransInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | 0 | BusinessRlnWithFamMemInd |
| Business Rln With Officer Ent | 0 | BusinessRlnWithOfficerEntInd |
| Deductible Non Cash Contri | 0 | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | 0 | DisregardedEntityInd |
| Related Entity | Yes (1) | RelatedEntityInd |
| Related Organization Ctrl Ent | Yes (1) | RelatedOrganizationCtrlEntInd |
| Transaction With Control Ent | 0 | TransactionWithControlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | 0 | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| IRP Document | 14 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (1) | BackupWthldComplianceInd |
| Employee | 80 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | 0 | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | 0 | ForeignFinancialAccountInd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | 0 | QuidProQuoContributionsInd |
| Form8282 Property Disposed Of | 0 | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | 0 | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | 0 | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 15 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 14 | IndependentVotingMemberCnt |
| Family Or Business Rln | Yes (1) | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | 0 | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | 0 | MembersOrStockholdersInd |
| Election Of Board Members | 0 | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | 0 | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (1) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (1) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (1) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (1) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (1) | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | AZ | StatesWhereCopyOfReturnIsFldCd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | ANNA M MIDKIFF CPA | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 5206478382 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1730 EAST RIVER ROAD NO 200 | AddressLine1Txt |
| City | TUCSON | CityNm |
| State Abbreviation | AZ | StateAbbreviationCd |
| ZIP | 857185898 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (22 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | OfficerOfficerInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd |
|---|---|---|---|---|---|---|---|
| D CRAIG BRATER MD | |||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | ||
| THE HONORABLE JAMES C GREENWOOD | |||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | ||
| KAY HOLCOMBE | |||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | ||
| MICHAEL KASSER MBA PHD | |||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | ||
| SHAUN A KIRKPATRICK MA | |||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | ||
| RICHARD T MYERS JR | |||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | ||
| CINDY PARSEGHIAN MBA | |||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | ||
| ALASTAIR JJ WOOD MB CHB | |||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | ||
| PETER BARTON HUTT LLB LLM | |||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | ||
| ALAN G LEVIN MS CPA | |||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | ||
| PAULA OLSIEWSKI PHD | |||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | ||
| JEFFREY E JACOB SM | |||||||
| DEPUTY CHAIRPERSON | 1.00 | Yes (X) | $0 | $0 | $0 | ||
| M WAINWRIGHT FISHBURN JR | |||||||
| VICE CHAIRPERSON | 1.00 | Yes (X) | $0 | $0 | $0 | Yes (X) | |
| TIMOTHY R FRANSON MD | |||||||
| CHAIRPERSON OF THE BOARD | 1.00 | Yes (X) | $0 | $0 | $0 | Yes (X) | |
| MARTHA BRUMFIELD PHD | |||||||
| CEO/PRESIDENT | 40.00 | Yes (X) | $296,591 | $0 | $29,794 | Yes (X) | |
| STEVEN BROADBENT MBA | |||||||
| COO/TREASURER | 40.00 | $194,127 | $0 | $26,519 | Yes (X) | ||
| LEWIS BARBIERI | |||||||
| SECRETARY | 40.00 | $114,661 | $0 | $18,817 | Yes (X) | ||
| LYNN D HUDSON PHD | |||||||
| EXECUTIVE DIRECTOR | 40.00 | $200,763 | $0 | $18,056 | Yes (X) | ||
| JOHN-MICHAEL SAUER PHD | |||||||
| EXECUTIVE DIRECTOR | 40.00 | $191,505 | $0 | $29,988 | Yes (X) | ||
| STEPHEN J COONS PHD | |||||||
| EXECUTIVE DIRECTOR | 40.00 | $185,620 | $0 | $21,631 | Yes (X) | ||
| STEVE ARNERIC PHD | |||||||
| EXECUTIVE DIRECTOR | 40.00 | $171,353 | $0 | $24,267 | Yes (X) | ||
| DEBRA HANNA PHD | |||||||
| EXECUTIVE DIRECTOR | 40.00 | $176,101 | $0 | $24,700 | Yes (X) | ||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $1,530,721 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $193,772 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 24 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | 0 | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt | Address Line1ContractorAddress/ForeignAddress/AddressLine1Txt | CityContractorAddress/ForeignAddress/CityNm | CountryContractorAddress/ForeignAddress/CountryCd | Foreign PostalContractorAddress/ForeignAddress/ForeignPostalCd |
|---|---|---|---|---|---|---|---|---|---|
| RESEARCH TRIANGLE INSTITUTE | |||||||||
| 200 PARK OFFICES DRIVE | RESEARCH TRIANGLE PARK | NC | 27709 | RESEARCH | $365,350 | ||||
| EPHIBIAN | |||||||||
| 3180 N SWAN ROAD | TUCSON | AZ | 85712 | IT SERVICES | $159,419 | ||||
| LOTOS NILE | |||||||||
| PO BOX 90245 | NASHVILLE | TN | 37209 | PUBLIC RELATIONS | $144,000 | ||||
| CLINICAL OUTCOME SOLUTIONS | |||||||||
| CLINICAL RESEARCH | $142,370 | UNIT 68 BASEPOINT SHEARWAY ROAD | FOLKESTONE | UK | CT19 4RH | ||||
| COVANCE LABORATORIES INC | |||||||||
| PO BOX 2464 | BURLINGTON | NC | 27216 | RESEARCH | $123,900 | ||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 14 | CntrctRcvdGreaterThan100KCnt |
| Government Grants | $3,480,022 | GovernmentGrantsAmt |
| All Other Contributions | $6,539,528 | AllOtherContributionsAmt |
| Total Contributions | $10,019,550 | TotalContributionsAmt |
Program Service Revenue ProgramServiceRevenueGrp (2 entries)
| DescDesc | BusinessBusinessCd | Total Revenue ColumnTotalRevenueColumnAmt | Related Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt |
|---|---|---|---|
| RESEARCH SUPPORT FEES | 541700 | $5,147,122 | $5,147,122 |
| OTHER REVENUE | 900099 | $17,487 | $17,487 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $5,164,609 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $83,667 | TotalRevenueColumnAmt |
| Exclusion | $83,667 | ExclusionAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $15,267,826 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $5,164,609 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $83,667 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part IX | Yes (X) | InfoInScheduleOPartIXInd |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,231,975 | TotalAmt |
| Program Services | $1,231,975 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $127,125 | TotalAmt |
| Program Services | $127,125 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $697,022 | TotalAmt |
| Program Services | $150,841 | ProgramServicesAmt |
| Management And General | $546,181 | ManagementAndGeneralAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $5,981,035 | TotalAmt |
| Program Services | $4,213,271 | ProgramServicesAmt |
| Management And General | $1,767,764 | ManagementAndGeneralAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $422,435 | TotalAmt |
| Program Services | $281,320 | ProgramServicesAmt |
| Management And General | $141,115 | ManagementAndGeneralAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $493,117 | TotalAmt |
| Program Services | $330,165 | ProgramServicesAmt |
| Management And General | $162,952 | ManagementAndGeneralAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $453,331 | TotalAmt |
| Program Services | $304,185 | ProgramServicesAmt |
| Management And General | $149,146 | ManagementAndGeneralAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $17,962 | TotalAmt |
| Program Services | $13,533 | ProgramServicesAmt |
| Management And General | $4,429 | ManagementAndGeneralAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $123,073 | TotalAmt |
| Program Services | $90,511 | ProgramServicesAmt |
| Management And General | $32,562 | ManagementAndGeneralAmt |
Fees For Services Lobbying FeesForServicesLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $60,284 | TotalAmt |
| Program Services | $57,964 | ProgramServicesAmt |
| Management And General | $2,320 | ManagementAndGeneralAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,436,169 | TotalAmt |
| Program Services | $2,359,796 | ProgramServicesAmt |
| Management And General | $76,373 | ManagementAndGeneralAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $205,483 | TotalAmt |
| Program Services | $138,274 | ProgramServicesAmt |
| Management And General | $67,209 | ManagementAndGeneralAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $355,357 | TotalAmt |
| Program Services | $314,960 | ProgramServicesAmt |
| Management And General | $40,397 | ManagementAndGeneralAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $366,686 | TotalAmt |
| Program Services | $303,966 | ProgramServicesAmt |
| Management And General | $62,720 | ManagementAndGeneralAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $523,915 | TotalAmt |
| Program Services | $96,591 | ProgramServicesAmt |
| Management And General | $427,324 | ManagementAndGeneralAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $460,119 | TotalAmt |
| Program Services | $438,449 | ProgramServicesAmt |
| Management And General | $21,670 | ManagementAndGeneralAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $388,900 | TotalAmt |
| Program Services | $379,065 | ProgramServicesAmt |
| Management And General | $9,835 | ManagementAndGeneralAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $32,303 | TotalAmt |
| Program Services | $21,675 | ProgramServicesAmt |
| Management And General | $10,628 | ManagementAndGeneralAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $55,137 | TotalAmt |
| Program Services | $36,997 | ProgramServicesAmt |
| Management And General | $18,140 | ManagementAndGeneralAmt |
Other Expenses OtherExpensesGrp (3 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt |
|---|---|---|---|
| DUES AND SUBSCRIPTIONS | $38,894 | $35,154 | $3,740 |
| BAD DEBT | $35,000 | $35,000 | |
| MISCELLANEOUS | $6,390 | $4,725 | $1,665 |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $14,511,712 | TotalAmt |
| Program Services | $10,965,542 | ProgramServicesAmt |
| Management And General | $3,546,170 | ManagementAndGeneralAmt |
| Fundraising | $0 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,969,152 | BOYAmt |
| EOY | $3,026,764 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $5,994,076 | BOYAmt |
| EOY | $4,831,456 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,212,619 | BOYAmt |
| EOY | $166,823 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $400,363 | BOYAmt |
| EOY | $596,248 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $159,773 | BOYAmt |
| EOY | $92,347 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $662,965 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $579,794 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $73,630 | BOYAmt |
| EOY | $83,171 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $6,674,273 | BOYAmt |
| EOY | $5,615,214 | EOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $24,325 | BOYAmt |
| EOY | $9,973 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $16,508,211 | BOYAmt |
| EOY | $14,421,996 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $753,078 | BOYAmt |
| EOY | $600,978 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $9,788,862 | BOYAmt |
| EOY | $7,098,633 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $10,541,940 | BOYAmt |
| EOY | $7,699,611 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows SFAS117 | Yes (X) | OrganizationFollowsSFAS117Ind |
Unrestricted Net Assets UnrestrictedNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $5,966,271 | BOYAmt |
| EOY | $6,722,385 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $5,966,271 | BOYAmt |
| EOY | $6,722,385 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $16,508,211 | BOYAmt |
| EOY | $14,421,996 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Reconcilation Revenue Expnss | $756,114 | ReconcilationRevenueExpnssAmt |
| Other Changes In Net Assets | $0 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | Yes (1) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Separate Basis Fincl Stmt | Yes (X) | SeparateBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (1) | AuditCommitteeInd |
| Federal Grant Audit Required | Yes (1) | FederalGrantAuditRequiredInd |
| Federal Grant Audit Performed | Yes (1) | FederalGrantAuditPerformedInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $5,370,782 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $10,269,811 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $10,197,464 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $10,085,049 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $10,019,550 | CurrentTaxYearAmt |
| Total | $45,942,656 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $5,370,782 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $10,269,811 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $10,197,464 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $10,085,049 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $10,019,550 | CurrentTaxYearAmt |
| Total | $45,942,656 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $21,404,373 | SubstantialContributorsTotAmt |
| Public Support Total170 | $24,538,283 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $70,230 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $82,059 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $80,580 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $48,471 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $83,667 | CurrentTaxYearAmt |
| Total | $365,007 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $46,307,663 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $22,488,531 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.52990 | PublicSupportCY170Pct |
| Public Support PY170 | 0.59930 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Schedule B IRS990ScheduleB
Schedule C IRS990ScheduleC
Total Direct Lobbying TotalDirectLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $60,816 | FilingOrganizationsTotalAmt |
Total Lobbying Expend TotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $60,816 | FilingOrganizationsTotalAmt |
Other Exempt Purpose Expend OtherExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $14,450,896 | FilingOrganizationsTotalAmt |
Total Exempt Purpose Expend TotalExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $14,511,712 | FilingOrganizationsTotalAmt |
Lobbying Nontaxable Amount LobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $875,586 | FilingOrganizationsTotalAmt |
Grassroots Nontaxable GrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $218,897 | FilingOrganizationsTotalAmt |
Tot Lbbyng Grassroot Mns Non Tx TotLbbyngGrassrootMnsNonTxGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Tot Lbby Expend Mns Lbbyng Non Tx TotLbbyExpendMnsLbbyngNonTxGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Avg Lobbying Nontaxable Amount AvgLobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $809,246 | CurrentYearMinus3Amt |
| Current Year Minus2 | $883,297 | CurrentYearMinus2Amt |
| Current Year Minus1 | $909,814 | CurrentYearMinus1Amt |
| Current Year | $875,586 | CurrentYearAmt |
| Total | $3,477,943 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Lobbying Ceiling | $5,216,915 | LobbyingCeilingAmt |
Avg Total Lobbying Expend AvgTotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $67,262 | CurrentYearMinus3Amt |
| Current Year Minus2 | $11,731 | CurrentYearMinus2Amt |
| Current Year Minus1 | $61,348 | CurrentYearMinus1Amt |
| Current Year | $60,816 | CurrentYearAmt |
| Total | $201,157 | TotalAmt |
Avg Grassroots Nontaxable AvgGrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $202,312 | CurrentYearMinus3Amt |
| Current Year Minus2 | $220,824 | CurrentYearMinus2Amt |
| Current Year Minus1 | $227,454 | CurrentYearMinus1Amt |
| Current Year | $218,897 | CurrentYearAmt |
| Total | $869,487 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grassroots Ceiling | $1,304,231 | GrassrootsCeilingAmt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART II-A, LINE 1B | FormAndLineReferenceDesc |
| Explanation | C-PATH SPENT A MINOR AMOUNT OF FUNDS ON LOBBYING IN FYE 06/30/2018. GENERALLY, C-PATH DOES NOT LOBBY FOR OR AGAINST ANY SPECIFIC LEGISLATION. C-PATH EXPENDS SOME TIME AND RESOURCES TO EDUCATE MEMBERS OF CONGRESS IN THE AREA OF DRUG DEVELOPMENT. | ExplanationTxt |
Schedule D IRS990ScheduleD
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $42,014 | OtherCostOrOtherBasisAmt |
| Depreciation | $39,338 | DepreciationAmt |
| Book Value | $2,676 | BookValueAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $179,139 | OtherCostOrOtherBasisAmt |
| Depreciation | $179,139 | DepreciationAmt |
| Book Value | $0 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $441,812 | OtherCostOrOtherBasisAmt |
| Depreciation | $361,317 | DepreciationAmt |
| Book Value | $80,495 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $83,171 | TotalBookValueLandBuildingsAmt |
| Footnote Text | Yes (X) | FootnoteTextInd |
| Total Rev Etc Audited Fincl Stmt | $15,267,826 | TotalRevEtcAuditedFinclStmtAmt |
| Revenue Not Reported | $0 | RevenueNotReportedAmt |
| Revenue Subtotal | $15,267,826 | RevenueSubtotalAmt |
| Revenue Not Reported Fincl Stmt | $0 | RevenueNotReportedFinclStmtAmt |
| Total Revenue Per Form990 | $15,267,826 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $14,511,712 | TotExpnsEtcAuditedFinclStmtAmt |
| Expenses Not Reported | $0 | ExpensesNotReportedAmt |
| Expenses Subtotal | $14,511,712 | ExpensesSubtotalAmt |
| Expenses Not Rpt Fincl Stmt | $0 | ExpensesNotRptFinclStmtAmt |
| Total Expenses Per Form990 | $14,511,712 | TotalExpensesPerForm990Amt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART X, LINE 2: | FormAndLineReferenceDesc |
| Explanation | FINANCIAL STATEMENT FIN 48 (ASC 740) FOOTNOTE: C-PATH IS EXEMPT FROM INCOME TAXES UNDER BOTH FEDERAL (INTERNAL REVENUE CODE SECTION 501(C)(3)) AND ARIZONA INCOME TAX LAWS, AND IS CLASSIFIED AS OTHER THAN A PRIVATE FOUNDATION UNDER INTERNAL REVENUE CODE SECTION 509(A)(2). INCOME FROM CERTAIN ACTIVITIES NOT DIRECTLY RELATED TO C-PATH'S TAX-EXEMPT PURPOSE, HOWEVER, MAY BE SUBJECT TO TAXATION AS UNRELATED BUSINESS TAXABLE INCOME (UBTI). GAAP REQUIRES MANAGEMENT TO PERFORM AN EVALUATION OF ALL TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN IN THE COURSE OF PREPARING C-PATH'S TAX RETURNS TO DETERMINE WHETHER THE TAX POSITIONS MEET A "MORE LIKELY THAN NOT" STANDARD OF BEING SUSTAINED UNDER EXAMINATION BY THE APPLICABLE TAXING AUTHORITIES. THIS EVALUATION IS REQUIRED TO BE PERFORMED FOR ALL OPEN TAX YEARS, AS DEFINED BY THE VARIOUS STATUTES OF LIMITATIONS, FOR FEDERAL AND STATE PURPOSES. C-PATH IS REQUIRED TO FILE INFORMATIONAL RETURNS FOR FEDERAL AND STATE PURPOSES AND, IF IT HAS UBTI, FEDERAL AND STATE INCOME TAX RETURNS. MANAGEMENT HAS PERFORMED ITS EVALUATION OF TAX POSITIONS TAKEN ON ALL OPEN TAX YEARS AND HAS DETERMINED THAT THERE WERE NO POSITIONS TAKEN THAT DO NOT MEET THE "MORE LIKELY THAN NOT" STANDARD. SHOULD C-PATH EVER BE SUBJECT TO PENALTIES AND INTEREST ASSESSED BY VARIOUS TAXING AUTHORITIES, THEY WOULD BE CLASSIFIED AS MANAGEMENT AND GENERAL EXPENSES. | ExplanationTxt |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Region | EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM | RegionTxt |
| Offices | 0 | OfficesCnt |
| Employee | 0 | EmployeeCnt |
| Type Of Activities Conducted | GRANTS TO RECIPIENTS LOCATED IN REGION | TypeOfActivitiesConductedTxt |
| Specific Services Provided | CLINICAL RESEARCH | SpecificServicesProvidedTxt |
| Region Total Expenditures | $127,125 | RegionTotalExpendituresAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 0 | SubtotalOfficesCnt |
| Subtotal Employees | 0 | SubtotalEmployeesCnt |
| Continuation Total Office | 0 | ContinuationTotalOfficeCnt |
| Continuation Total Employee | 0 | ContinuationTotalEmployeeCnt |
| Total Office | 0 | TotalOfficeCnt |
| Total Employee | 0 | TotalEmployeeCnt |
| Subtotal Spent | $127,125 | SubtotalSpentAmt |
| Continuation Spent | $0 | ContinuationSpentAmt |
| Total Spent | $127,125 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Region | EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM | RegionTxt |
| Purpose Of Grant | CLINICAL RESEARCH | PurposeOfGrantTxt |
| Cash Grant | $127,125 | CashGrantAmt |
| Manner Of Cash Disbursement | WIRE TRANSFER | MannerOfCashDisbursementTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Org | 1 | TotalOtherOrgCnt |
| Transfer To Foreign Corp | 0 | TransferToForeignCorpInd |
| Interest In Foreign Trust | 0 | InterestInForeignTrustInd |
| Foreign Corp Ownership | Yes (1) | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | 0 | PassiveForeignInvestmestCoInd |
| Foreign Partnership | 0 | ForeignPartnershipInd |
| Boycott Countries | 0 | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | CRITICAL PATH INSTITUTE ENTERS INTO SUBAWARD AGREEMENTS WITH SUBRECIPIENTS AND REVIEWS PROGRESS DELIVERABLES AND COSTS. | ExplanationTxt |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (6 entries)
| Address Line1USAddress/AddressLine1Txt | Address Line2USAddress/AddressLine2Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Purpose Of GrantPurposeOfGrantTxt |
|---|---|---|---|---|---|---|---|---|
| BAYLOR RESEARCH INSTITUTE | ||||||||
| 1950 N STEMMONS FREEWAY SUITE 5010 | LOCKBOX 846275 | DALLAS | TX | 75207 | 751921898 | 501(C)(3) | $400,459 | DEVELOP A HOLLOW FIBER MODEL FOR TUBERCULOSIS RESEARCH |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | ||||||||
| 1855 FOLSOM STREET BOX 0897 | SAN FRANCISCO | CA | 94143 | 946036493 | STATE OF CALIFORNIA | $173,425 | DEVELOP A DISEASE PROGRESSION MODEL FOR TUBERCULOSIS | |
| UNIVERSITY OF FLORIDA | ||||||||
| PO BOX 113001 | GAINSVILLE | FL | 32611 | 596002052 | STATE OF FLORIDA | $55,100 | DEVELOP A POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODEL FOR TUBERCULOSIS | |
| CLINICAL DATA INTERCHANGE STANDARDS CONSORTIUM | ||||||||
| PO BOX 2068 | ROUND ROCK | TX | 78680 | 043503931 | 501(C)(3) | $263,981 | DEVELOP CLINICAL DATA STANDARDS | |
| THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE | ||||||||
| 445 N FIFTH STREET SUITE 600 | PHOENIX | AZ | 85004 | 753065445 | 501(C)(3) | $293,585 | DEVELOP THE RESEQTB INTEGRATED PIPELINE | |
| FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH INC | ||||||||
| 9650 ROCKVILLE PIKE SUITE 3411 | BETHESDA | MD | 20814 | 521986675 | 501(C)(3) | $45,425 | CLINICAL EVALUATION AND QUALIFICATION OF KIDNEY SAFETY BIOMARKERS STUDY | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 6 | Total501c3OrgCnt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | CRITICAL PATH INSTITUTE ENTERS INTO SUBAWARD AGREEMENTS WITH SUBRECIPIENTS AND REVIEWS PROGRESS DELIVERABLES AND COSTS. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Form990 Of Other Organizations | Yes (X) | Form990OfOtherOrganizationsInd |
| Written Employment Contract | Yes (X) | WrittenEmploymentContractInd |
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | 0 | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | 0 | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | 0 | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | 0 | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | 0 | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | 0 | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | 0 | AnyNonFixedPaymentsInd |
| Initial Contract Exception | 0 | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (7 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MARTHA BRUMFIELD PHD | ||||||||||||||
| CEO/PRESIDENT | $296,591 | $0 | $0 | $0 | $0 | $0 | $22,600 | $0 | $7,194 | $0 | $326,385 | $0 | $0 | $0 |
| STEVEN BROADBENT MBA | ||||||||||||||
| COO/TREASURER | $194,127 | $0 | $0 | $0 | $0 | $0 | $15,509 | $0 | $11,010 | $0 | $220,646 | $0 | $0 | $0 |
| LYNN D HUDSON PHD | ||||||||||||||
| EXECUTIVE DIRECTOR | $200,763 | $0 | $0 | $0 | $0 | $0 | $15,716 | $0 | $2,340 | $0 | $218,819 | $0 | $0 | $0 |
| JOHN-MICHAEL SAUER PHD | ||||||||||||||
| EXECUTIVE DIRECTOR | $191,505 | $0 | $0 | $0 | $0 | $0 | $15,681 | $0 | $14,307 | $0 | $221,493 | $0 | $0 | $0 |
| STEPHEN J COONS PHD | ||||||||||||||
| EXECUTIVE DIRECTOR | $185,620 | $0 | $0 | $0 | $0 | $0 | $14,729 | $0 | $6,902 | $0 | $207,251 | $0 | $0 | $0 |
| STEVE ARNERIC PHD | ||||||||||||||
| EXECUTIVE DIRECTOR | $171,353 | $0 | $0 | $0 | $0 | $0 | $13,371 | $0 | $10,896 | $0 | $195,620 | $0 | $0 | $0 |
| DEBRA HANNA PHD | ||||||||||||||
| EXECUTIVE DIRECTOR | $176,101 | $0 | $0 | $0 | $0 | $0 | $14,520 | $0 | $10,180 | $0 | $200,801 | $0 | $0 | $0 |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (8 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART III, LINE 4A, PROGRAM SERVICE ACCOMPLISHMENTS | THE CRITICAL PATH INSTITUTE (C-PATH) IS AN INDEPENDENT, NON-PROFIT ORGANIZATION UNIQUELY DEDICATED TO ADVANCING MULTIPLE ASPECTS OF THE FDA'S CRITICAL PATH INITIATIVE BY CREATING COLLABORATIONS AMONG REGULATORS (SCIENTISTS FROM THE FDA AND EMA), THE REGULATED MEDICAL PRODUCT INDUSTRY, ACADEMIA, PATIENT GROUPS, AND OTHER ORGANIZATIONS THAT ADVANCE MEDICAL INNOVATION THROUGH THE DEVELOPMENT OF TOOLS AND METHODS BASED UPON SOUND, CONSENSUS-BASED SCIENCE. THE ACCOMPLISHMENTS FOR THIS FISCAL YEAR REPORT INCLUDE: THE COALITION AGAINST MAJOR DISEASES WAS REBRANDED AS THE CRITICAL PATH FOR ALZHEIMER'S DISEASE. IT DEVELOPS TOOLS AND NOVEL METHODOLOGIES TO ACCELERATE PROGRESS IN THE DEVELOPMENT OF PREVENTION AND TREATMENT STRATEGIES FOR ALZHEIMER'S DISEASE. THIS YEAR'S ACCOMPLISHMENTS INCLUDE: (1) RECEIVING A LETTER OF SUPPORT FROM THE EMA ENCOURAGING INDUSTRY SPONSORS TO SHARE WITH CPAD THE PATIENT-LEVEL DATA FROM COMPLETED PHASE II AND III CLINICAL TRIALS, INCLUDING ACTIVE AND CONTROL ARMS, ALLOWING CPAD TO COMPLETE DEVELOPMENT AND VALIDATION OF A PROPOSED QUANTITATIVE MODEL FOR IMPLEMENTATION BY SPONSORS ACTIVELY DESIGNING CLINICAL TRIALS IN AMNESTIC MILD COGNITIVE IMPAIRMENT (AMCI). (2) GENERATED GRAPHICAL USER INTERFACE-BASED UPDATES TO THE AD MILD-TO-MODERATE CLINICAL TRIAL SIMULATION TOOL AND MILD COGNITIVE IMPAIRMENT (MCI) CLINICAL TRIAL SIMULATION TOOL - THE HIPPOCAMPAL NEUROIMAGING-INFORMED AMNESTIC MCI CLINICAL TRIAL SIMULATOR. (3) INCREASED USE OF THE DATABASE AND MODELS. THE CRITICAL PATH FOR PARKINSON'S CONSORTIUM'S GOALS ARE TO DEVELOP QUANTITATIVE MODEL-BASED TOOLS TO ACCELERATE THE TREATMENT OF PARKINSON'S DISEASE, ESPECIALLY FOR THOSE INDIVIDUALS EXPERIENCING THE FIRST CLINICAL SIGNS OF MOTOR SYMPTOM ONSET. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE:(1) SUBMISSION TO EMA AND FDA OF THE FIRST MODELING TOOL FOR PARKINSON'S- "MODEL-BASED CLINICAL TRIAL ENRICHMENT TOOL FOR PARKINSON DISEASE CLINICAL TRIALS". (2) RECEIVED FDA'S FORMAL RESPONSE TO CPP'S LETTER OF INTENT OUTLINING RECOMMENDATIONS FOR WHAT SHOULD BE SUBMITTED IN THE MODELING BRIEFING DOCUMENT. (3) EMA QUALIFICATION ADVICE LETTER RECEIVED FOR THE MODEL-BASED CLINICAL TRIAL ENRICHMENT TOOL FOR PARKINSON'S DISEASE CLINICAL TRIALS. THE MISSION OF THE CRITICAL PATH TO TB DRUG REGIMENS INITIATIVE IS TO ACCELERATE THE DEVELOPMENT OF NOVEL TB DRUG REGIMENS THAT ARE SAFER, SHORTER, AND MORE EFFICACIOUS THAN THE CURRENT STANDARD OF CARE. THEIR MISSION EXPANDED TO ACCELERATE THE DEVELOPMENT OF A CLINICALLY USEFUL IN VITRO RAPID DRUG SUSCEPTIBILITY ASSAY TO SUPPORT TB REGIMEN DEVELOPMENT AND DEPLOYMENT. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) ELEVEN NEW TB CLINICAL DATASETS WERE ACQUIRED, CURATED, AND INTEGRATED INTO THE TB PLATFORM FOR AGGREGATION OF CLINICAL TB STUDIES (TB-PACTS) PLATFORM AND MADE ACCESSIBLE TO QUALIFIED RESEARCHERS. TO DATE, OVER 55 APPLICATIONS HAVE BEEN SUBMITTED AND 42 HAVE BEEN APPROVED TO SUPPORT TB RESEARCH. (2) COMPLETED THE STAGE 2 ANALYSIS OF TB RE-ANALYSIS OF FLUOROQUINOLONE EXECUTED CLINICAL TRIALS (TB-REFLECT), WHICH FOCUSED ON ISONIAZID RESISTANT SUB-COHORT AND EXAMINATION OF SAFETY FINDINGS FOR STANDARD OF CARE REGIMENS WHICH CONTAIN A FLUOROQUINOLONE. (3) COMPLETED OR SIGNIFICANTLY ADVANCED THE FOLLOWING MODELING AND SIMULATION PROJECTS: POPULATION PK/PD, LIQUID CULTURE, QUANTITATIVE SYSTEMS PHARMACOLOGY, AND CARDIAC RISK ASSESSMENT ALGORITHM. ADDITIONALLY, HFS-TB EXPERIMENTS CHARACTERIZING THE PK/PD ATTRIBUTES OF THREE DRUGS AND REGIMENS FOR TB HAVE BEEN COMPLETED, WITH FOUR EXPERIMENTS ONGOING. OTHER MODEL-BASED ANALYSES ARE ONGOING TO IDENTIFY PREFERRED METHODS FOR THE TRANSLATION OF DATA FROM IN VITRO AND IN VIVO (ANIMAL) MODELS TO PREDICT CLINICAL OUTCOMES FOR ANTI-TB DRUGS AND REGIMENS. (4) EXPANDED ANALYSES TO SUPPORT PBPK QUALIFICATION EFFORTS BASED ON FEEDBACK FROM EMA'S SCIENTIFIC ADVICE WORKING PARTY (SAWP). FURTHER ANALYSES DESIGNED TO VERIFY PBPK GRANULOMA MODEL PERFORMANCE ARE IN PROGRESS. THE DATA COLLABORATION CENTER IS A CENTER WITHIN C-PATH TO ENABLE MULTIPLE ORGANIZATIONS TO WORK TOGETHER IN A NEUTRAL SETTING AND SHARE CLINICAL DATA IN ORDER TO OPTIMIZE ITS VALUE IN CREATING NEW INSIGHTS AND TOOLS THAT ACCELERATE DRUG DEVELOPMENT IN AREAS WITH UNMET MEDICAL NEEDS. THE DCC SUPPORTS DATA SHARING PROJECTS ALIGNED WITH SPECIFIC C-PATH CONSORTIA AS WELL AS DATA SHARING INITIATIVES THAT ARE INDEPENDENT OF C-PATH CONSORTIA. ITS ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) LAUNCHED THE DUCHENNE'S REGULATORY SCIENCE CONSORTIUM (D-RSC) DATABASE WHICH WILL BE USED IN THE DEVELOPMENT OF A DMD DISEASE PROGRESSION MODEL AND CLINICAL TRIAL SIMULATION PLATFORM. (2) LAUNCHED THE CATALYSIS FOUNDATION ONLINE DATA REPOSITORY TO PROVIDE A PLATFORM TO MAKE DATASETS FROM A TREATMENT RESPONSE BIOMARKER STUDY OF TB POSITIVE, HIV NEGATIVE PATIENTS AVAILABLE TO QUALIFIED TB RESEARCHERS. (3) LAUNCHED THE FRIEDREICH'S ATAXIA INTEGRATED CLINICAL DATABASE FOR USE BY QUALIFIED RESEARCHERS. (4) RELEASED TB-PACTS VERSION 2.0 CONTAINING DATA FROM 14 NEW TB STUDIES FOR A TOTAL OF 17. THE DUCHENNE REGULATORY SCIENCE CONSORTIUM'S GOAL IS TO SUPPORT COLLABORATIVE RESEARCH AND REGULATORY QUALIFICATION OF NEW DRUG DEVELOPMENT TOOLS FOR DUCHENNE MUSCULAR DYSTROPHY, TO ENABLE THE EARLIEST POSSIBLE PATIENT ACCESS TO NEW TREATMENTS. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) ACQUIRED TWELVE DATASETS, AND DATA SHARING AGREEMENTS FOR ADDITIONAL DATASETS ARE UNDERWAY. PRESENTLY, ~1,100 INDIVIDUAL PATIENT RECORDS ARE INCLUDED IN THE D-RSC DATABASE, EXCLUDING DATA FROM A PATIENT REPORTED REGISTRY THAT WILL NOT BE USED FOR ANALYSIS. APPROXIMATELY 4000-5000 DATA-POINTS ARE IN THE DATABASE FOR EACH MEASURE OF INTEREST. PARTS OF THE DATABASE ARE OPEN FOR USE BY CONSORTIUM MEMBERS AND HAVE BEEN USED BY AT LEAST FOUR COMPANY MEMBERS AND BY PPMD IN SUPPORT OF INITIAL ANALYSIS AROUND THE DEVELOPMENT OF THE DUCHENNE PLATFORM TRIAL. (2) PUBLISHED THE CDISC THERAPEUTIC AREA USER GUIDE. (3) DEVELOPMENT OF THE LETTER OF INTENT AND MODELING PLAN ARE UNDERWAY. THE GOAL OF THE ELECTRONIC PATIENT-REPORTED OUTCOME CONSORTIUM IS TO ADVANCE THE SCIENCE OF CLINICAL TRIAL ENDPOINT ASSESSMENT BY COLLABORATIVELY SUPPORTING AND CONDUCTING RESEARCH, DESIGNING AND DELIVERING EDUCATIONAL OPPORTUNITIES, AND DEVELOPING AND DISSEMINATING BEST PRACTICE RECOMMENDATIONS FOR ELECTRONIC COLLECTION OF CLINICAL OUTCOME DATA. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) CONTRIBUTED TO EMA'S GOOD CLINICAL PRACTICE INSPECTORS WORKING GROUP (GCP IWG) BY OFFERING THE EPRO CONSORTIUM'S STAKEHOLDER PERSPECTIVE DURING PAST MEETING OF THE GCP IWG ON TOPICS SUCH AS: RESPONSIBILITIES OF EPRO PROVIDERS REGARDING SOURCE DATA, USE OF ELECTRONIC INFORMED CONSENT, AND RESPONSIBILITIES OF EPRO PROVIDERS WHEN COLLECTING ELECTRONIC SIGNATURES. C-PATH LAUNCHED A NEW CONSORTIUM IN PARTNERSHIP WITH CHDI FOUNDATION TO WORK ON DRUG DEVELOPMENT TOOLS FOR HUNTINGTON'S DISEASE. THE ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) RECRUITED 14 INDUSTRY PARTNERS AND 16 SCIENTIFIC ADVISORS. (2) DEVELOPED AND PUBLISHED THE CDISC HD-SPECIFIC THERAPEUTIC AREA USER GUIDE. (3) CREATED A COMPREHENSIVE INVENTORY OF HD CLINICAL DATA SETS AND MODELING AND SIMULATION TOOLS. (4) ACQUIRED THE FIRST TWO DATA SETS, ENROLL-HD, AN ONGOING NATURAL HISTORY STUDY THAT INCLUDES 8000 SUBJECTS, AND TRACK-HD, A COMPLETED OBSERVATIONAL STUDY THAT INVESTIGATED POTENTIAL OUTCOME MEASURES IN OVER 300 SUBJECTS. ACTIVE CONVERSATIONS ARE ONGOING WITH FOUR ADDITIONAL DATA CONTRIBUTORS. (5) LAUNCHED WORKING GROUP ACTIVITIES WITH FOCUS ON CONTEXT-OF-USE, CRITERIA FOR REGULATORY READINESS OF BIOMARKERS, AND AN IMMEDIATE ACTION PLAN TO SEEK REGULATORY FEEDBACK ON CLINICAL OUTCOME ASSESSMENTS CURRENTLY IN DEVELOPMENT. |
| FORM 990, PART III, LINE 4A | AT THE REQUEST OF THE FDA, C-PATH FORMED AN INTERNATIONAL NEONATAL CONSORTIUM (INC). THE PURPOSE OF THE CONSORTIUM IS TO ACCELERATE THE DEVELOPMENT OF SAFE AND EFFECTIVE THERAPIES FOR NEONATES. INC ENGAGES THE GLOBAL NEONATAL COMMUNITY - FAMILIES, NEONATAL NURSES, ACADEMIC SCIENTISTS, REGULATORS, PHARMACEUTICAL INVESTIGATORS, ADVOCACY ORGANIZATIONS, AND FUNDERS - TO FOCUS ON THE NEEDS OF THE NEONATE. THIS PAST YEAR INC'S CLINICAL PHARMACOLOGY WORKGROUP DEVELOPED A WHITE PAPER TO ASSIST REGULATORS IN PREPARING GUIDANCE ON THE CLINICAL PHARMACOLOGY CONSIDERATIONS FOR NEONATES, INCLUDING RECOMMENDATIONS FOR SAFER FORMULATIONS ENCOMPASSING EASE OF ADMINISTRATION. INC'S BRONCHOPULMONARY DYSPLASIA (BPD) WORKGROUP DESCRIBED POTENTIAL ENDPOINTS FOR TRIALS TO EVALUATE TREATMENTS FOR CHRONIC PULMONARY INSUFFICIENCY OF PREMATURITY (CPIP). INC'S SEIZURE WORKGROUP DEVELOPED RECOMMENDATIONS FOR USE IN A MASTER PROTOCOL TO EVALUATE MEDICATIONS TO TREAT NEONATAL SEIZURES. INC'S DATA WORKGROUP REVIEWED THE VALUE AND NEEDS FOR SHARING NEONATAL DATA AND PROPOSED A GLOBAL APPROACH TO COLLECTING, STANDARDIZING, AND SHARING DATA. INC'S CLINICAL PHARMACOLOGY ADVERSE EVENT SUBGROUP COMPLETED DEVELOPMENT OF THE NEONATAL ADVERSE EVENT SEVERITY GRADING SCALE (NAESS) AND HAVE INCORPORATED THE NEW AE TERMINOLOGY INTO THE NATIONAL CANCER INSTITUTE - ENTERPRISE VOCABULARY SERVICES (NCI-EVS) ONLINE THESAURUS. INC SUBMITTED COMMENTS ON THE NOTICE OF PROPOSED RULEMAKING (NPRM) "FEDERAL POLICY FOR THE PROTECTION OF HUMAN SUBJECTS" TO U.S. HEALTH AND HUMAN SERVICES' OFFICE FOR HUMAN RESEARCH PROTECTIONS AND ALSO SUPPLIED INPUT ON DRUGS AND THERAPEUTIC AREAS THAT REQUIRE FURTHER STUDY IN NEONATES, IN RESPONSE TO NATIONAL INSTITUTE OF CHILD HEALTH AND DEVELOPMENT'S REQUEST FOR INFORMATION ON THE BEST PHARMACEUTICALS FOR CHILDREN ACT PRIORITIES IN PEDIATRIC THERAPEUTICS 2017. THE MULTIPLE SCLEROSIS OUTCOME ASSESSMENTS CONSORTIUM HAS A GOAL TO OBTAIN REGULATORY QUALIFICATION OF AN IMPROVED CLINICAL OUTCOME ASSESSMENT INSTRUMENT AS A PRIMARY OR SECONDARY ENDPOINT IN CLINICAL TRIALS OF MULTIPLE SCLEROSIS (MS) THERAPIES. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) EXECUTED THE STATISTICAL ANALYSIS PLAN (FOR A SINGLE MEASURE) DEVELOPED FOR FDA AND SUBMITTED THE FINAL QUALIFICATION PACKAGE. (2) EXECUTED THE STATISTICAL ANALYSIS PLAN (INCLUDING FOUR MEASURES) DEVELOPED FOR EMA AND THE "VOICE OF THE PATIENT" METHODOLOGY AND SUBMITTED THE FINAL QUALIFICATION PACKAGE TO THE EMA. THE POLYCYSTIC KIDNEY DISEASE OUTCOMES CONSORTIUM HAS DEVELOPED AND OBTAINED REGULATORY QUALIFICATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) AND THE EUROPEAN MEDICINES AGENCY (EMA) OF TOTAL KIDNEY VOLUME (TKV) AS A PROGNOSTIC BIOMARKER FOR USE IN CLINICAL TRIALS FOR NEW THERAPIES FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD). THE CONSORTIUM CONTINUES TO EXPLORE ALTERNATE CLINICAL ENDPOINTS, INCLUDING A COMPOSITE ENDPOINT, INNOVATIVE CLINICAL TRIAL DESIGNS, AND REGULATORY PATHWAYS TO HELP EXPEDITE NEW THERAPIES IN PKD. THE FDA HAS COMMUNICATED THAT TKV IS A "REASONABLY LIKELY SURROGATE," WHICH MAKES IT ELIGIBLE FOR AN ACCELERATED APPROVAL PROCESS AT THE FDA. SIX NEW COMPANIES ARE NOW WORKING TO DEVELOP THERAPIES FOR THIS DISEASE. THE FDA APPROVED OTSUKA'S DRUG (JYNARQUETM). THIS IS THE FIRST-EVER FDA-APPROVED TREATMENT FOR PKD. ALTHOUGH IT WAS NOT A DIRECT OUTPUT OF PKDOC, THE CONSORTIUM'S WORK POSITIVELY CONTRIBUTED TO ADVANCES IN THE FIELD CONSISTENT WITH THIS SUCCESS STORY. THE PATIENT-REPORTED OUTCOME CONSORTIUM HAS A GOAL TO ESTABLISH AND MAINTAIN A COLLABORATIVE FRAMEWORK WITH APPROPRIATE STAKEHOLDERS FOR THE QUALIFICATION OF PATIENT-REPORTED OUTCOME (PRO) INSTRUMENTS AND OTHER CLINICAL OUTCOME ASSESSMENT (COA) TOOLS THAT WILL BE MADE AVAILABLE FOR USE IN CLINICAL TRIALS WHERE COA-BASED ENDPOINTS ARE USED TO SUPPORT PRODUCT LABELING CLAIMS. TWO PRO MEASURES WERE QUALIFIED BY FDA FOR EXPLORATORY USE, THE SYMPTOMS OF MAJOR DEPRESSIVE DISORDER SCALE (SMDDS) AND THE NON-SMALL CELL LUNG CANCER SYMPTOM ASSESSMENT QUESTIONNAIRE (NSCLC-SAQ). OTHER PRO MEASURES WHICH HAVE BEEN SUBMITTED TO FDA FOR QUALIFICATION FOR EXPLORATORY USE INCLUDE: (1) THE ASTHMA DAILY SYMPTOM DIARY (ADSD) AND (2) THE FUNCTIONAL DYSPEPSIA SYMPTOM DIARY (FDSD). THE PRO CONSORTIUM HAS ISSUED A TOTAL OF 10 LICENSES FOR USE OF PRO CONSORTIUM MEASURES INCLUDING THE SMDDS, THE NSCLCSAQ, AND THE MYELOFIBROSIS SYMPTOM ASSESSMENT FORM V4.0 (MFSAF V4.0). THE FOLLOWING COAS ARE IN VARIOUS STAGES OF THE DEVELOPMENT AND/OR QUALIFICATION PROCESS: UCSD PERFORMANCE-BASED SKILLS ASSESSMENT FOR MILD COGNITIVE IMPAIRMENT (UPSA-MCI), DIARY FOR IRRITABLE BOWEL SYNDROME SYMPTOMS-C (DIBSS-C) FOR CONSTIPATION PREDOMINANT IBS, DIARY FOR IRRITABLE BOWEL SYNDROME SYMPTOMS-D (DIBSS-D) FOR DIARRHEA PREDOMINANT IBS, DIARY FOR IRRITABLE BOWEL SYNDROME SYMPTOMS-M (DIBSS-M) FOR MIXED IBS, AN OPTIMIZED PROMIS PHYSICAL FUNCTION SHORT FORM FOR MS PATIENTS, PEDIATRIC ASTHMA DIARY - OBSERVER (PAD-O), PEDIATRIC ASTHMA DIARY - CHILD (PAD-C), RHEUMATOID ARTHRITIS WG - PROMIS SHORT FORM V1.0 - FATIGUE 10A. THE PREDICTIVE SAFETY TESTING CONSORTIUM HAS A GOAL TO BRING TOGETHER PHARMACEUTICAL COMPANIES TO SHARE AND VALIDATE INNOVATIVE SAFETY TESTING METHODS UNDER ADVISEMENT OF THE U.S. FOOD AND DRUG ADMINISTRATION (FDA), EUROPEAN MEDICINES AGENCY (EMA), AND JAPAN'S PHARMACEUTICALS AND MEDICAL DEVICES AGENCY (PMDA). CURRENTLY PSTC IS FOCUSED ON DEVELOPING AND OBTAINING REGULATORY QUALIFICATION OF IMPROVED CLINICAL SAFETY BIOMARKERS FOR USE IN DRUG DEVELOPMENT. THIS YEAR THE CONSORTIUM'S ACCOMPLISHMENTS INCLUDE: (1) IN COOPERATION WITH THE FDA, LAUNCHED THE PILOT BIOMARKER DATA REPOSITORY (BMDR) PROJECT DESIGNED TO COLLECT AND ANALYZE KIDNEY SAFETY BIOMARKER DATA. (2) RECEIVED A LETTER OF SUPPORT FROM EMA FOR THE USE OF GLUTAMATE DEHYDROGENASE (GLDH), A SPECIFIC BIOMARKER OF DRUG-INDUCED HEPATIC INJURY IN HUMANS. (3) ACHIEVED FDA QUALIFICATION OF A PANEL OF CLINICAL DRUG-INDUCED KIDNEY INJURY BIOMARKERS FOR USE IN PHASE 1 CLINICAL TRIALS. THE TYPE I DIABETES CONSORTIUM (T1D) IS FOCUSING ON QUALIFYING ISLET AUTOIMMUNITY ANTIBODIES AS SUSCEPTIBILITY/RISK BIOMARKERS TO BE USED IN THE DEVELOPMENT OF THERAPIES FOR THE TREATMENT, AND ULTIMATELY, THE PREVENTION, OF TYPE 1 DIABETES. THIS YEAR T1D SECURED THE FOLLOWING DATA SETS AND IS CURRENTLY WORKING TO BUILD AN INTEGRATED DATABASE TO SUPPORT QUALIFICATION: THE COLORADO DIABETES AUTOIMMUNITY STUDY IN THE YOUNG (DAISY), THE ENVIRONMENTAL DETERMINANTS OF DIABETES IN THE YOUNG (TEDDY), TRIALNET NATURAL HISTORY STUDY (TN01-NH), THE GERMAN BABYDIAB AND BABYDIET STUDIES, AND THE DIABETES PREVENTION TRIAL (DPT-1). THE CONSORTIUM SUBMITTED A LETTER OF INTENT TO FDA AND RECEIVED A POSITIVE RESPONSE TO THE LETTER OF INTENT FROM THE FDA AND WAS ASKED TO PROCEED TO THE NEXT STEP IN THE QUALIFICATION PROCESS: THE DEVELOPMENT OF THE QUALIFICATION PLAN. THE CONSORTIUM IS NOW WORKING ON THE DRAFTING OF THE QUALIFICATION PLAN FOCUSING, IN PART, ON THE BUILDING OF AN ASSAY PUBLICATION LIBRARY AND REVIEWING THE ASSAY METHODOLOGY USED FOR ALL DATA TO COMPLETE THE ANALYTICAL CONSIDERATIONS SECTION OF THE DOCUMENT. THE CONSORTIUM HAS INITIATED CONSTRUCTION OF A MODELING ANALYSIS PLAN TO ENABLE THE GENERATION OF THE T1D DISEASE PROGRESSION MODEL REQUIRED TO SUPPORT THE REGULATORY ENDORSEMENT OF THE ISLET AUTOANTIBODIES. THE TRANSPLANTATION THERAPEUTICS CONSORTIUM IS WORKING TO IDENTIFY MECHANISMS AND DRUG DEVELOPMENT TOOLS TO ACCELERATE DRUG DISCOVERY FOR TRANSPLANT PATIENTS, THROUGH THE COLLABORATIVE INVOLVEMENT OF KEY STAKEHOLDERS IN THE FIELD. THE CONSORTIUM IS INITIALLY FOCUSING ON KIDNEY TRANSPLANT BUT MAY EXPAND TO OTHER SOLID ORGAN TRANSPLANTS IN THE FUTURE. THIS YEAR THE TTC INITIATED TWO WORKGROUPS, THE ENDPOINTS AND BIOMARKERS WORKGROUP, AND THE DRUG SAFETY PROFILE CHARACTERIZATION AND LABELING WORKGROUP. THE INITIAL FOCUS OF THE CONSORTIUM IS TO SEEK FDA ENDORSEMENT FOR A QUANTITATIVE DRUG DEVELOPMENT TOOL CAPABLE OF OPTIMIZING CLINICAL TRIAL DESIGNS IN KIDNEY TRANSPLANTATION, BY INFORMING SPONSOR DECISION MAKING REGARDING CLINICAL TRIAL DESIGN, SIZE, AND DURATION, OPTIMIZE DOSING STRATEGIES, PREDICT SAFETY SIGNALS, SUPPORT EVIDENCE OF EFFECTIVENESS, AND ENDPOINT SELECTION. THROUGH FDA'S BROAD AGENCY ANNOUNCEMENT PROCEDURE, TTC RECEIVED FUNDING TO SUPPORT THE INITIAL FOCUS AREA OF DEVELOPING A MODEL. |
| FORM 990, PART VI, SECTION A, LINE 2 | MIKE KASSER AND JEFF JACOB HAVE A BUSINESS RELATIONSHIP. PETER HUTT AND JEFF JACOB HAVE A BUSINESS RELATIONSHIP. WAIN FISHBURN AND JEFF JACOB HAVE A BUSINESS RELATIONSHIP. JEFF JACOB AND SHAUN KIRKPATRICK HAVE A BUSINESS RELATIONSHIP. |
| FORM 990, PART VI, SECTION B, LINE 11B | FORM 990 IS PREPARED BY AN EXTERNAL CPA FIRM USING INFORMATION PROVIDED BY THE ORGANIZATION. THE FORM IS REVIEWED BY THE ORGANIZATION'S COMPTROLLER, COO, PRESIDENT/CEO, THE BOARD AUDIT, FINANCE, AND RISK COMMITTEE, AND THE BOARD OF DIRECTORS PRIOR TO BEING FINALIZED. |
| FORM 990, PART VI, SECTION B, LINE 12C | ALL MEMBERS OF THE BOARD OF DIRECTORS AND ALL OFFICERS OF THE ORGANIZATION ARE REQUIRED TO FILL OUT A CONFLICT OF INTEREST FORM ANNUALLY. THE RESULTS ARE COMPILED AND REVIEWED BY THE BOARD'S AUDIT, FINANCE, AND RISK COMMITTEE. ANY ACTUAL OR PERCEIVED CONFLICTS THAT HAVE THE POTENTIAL TO BIAS ANY DISCUSSIONS OR DECISIONS BY THE BOARD ARE DISCUSSED BY THE BOARD. ANY DIRECTOR WITH A REAL OR POTENTIAL CONFLICT WILL RECUSE THEMSELVES FROM ANY DISCUSSION OR DECISION WHERE THE CONFLICT HAS A BEARING. |
| FORM 990, PART VI, SECTION B, LINE 15 | A BOARD OF DIRECTORS COMPENSATION COMMITTEE MEETS AND REVIEWS EXECUTIVE COMPENSATION ANNUALLY. EVERY FEW YEARS THE COMMITTEE SEEKS AN INDEPENDENT COMPENSATION CONSULTING ORGANIZATION. AFTER THE CONSULTING ORGANIZATION HAS BEEN RETAINED, THE COMPENSATION COMMITTEE RECEIVES THE CONSULTANT'S EXECUTIVE COMPENSATION REVIEWS AND RECOMMENDATIONS. THIS INFORMATION IS THEN USED AS A BASIS FOR THE COMPENSATION COMMITTEE'S RECOMMENDATION TO THE BOARD OF DIRECTORS. THE LAST INDEPENDENT COMPENSATION SURVEY WAS CONDUCTED FOR THE CEO IN AUGUST 2011. THE CEO'S SALARY HAS REMAINED CONSTANT SINCE THE TIME OF HER HIRE. AN OVERALL SALARY PROGRAM FOR EMPLOYEES, WHICH IS DEVELOPED BASED ON SALARY SURVEY INFORMATION, MUST BE APPROVED BY THE BOARD OF DIRECTORS COMPENSATION COMMITTEE BEFORE IMPLEMENTATION. ALL EMPLOYEE SALARY INCREASES MUST BE APPROVED BY THE PRESIDENT/CEO. |
| FORM 990, PART VI, SECTION C, LINE 19 | ARTICLES OF INCORPORATION CAN BE FOUND ON THE ARIZONA CORPORATION COMMISSION WEBSITE. THE CONFLICT OF INTEREST POLICY AND THE FINANCIAL STATEMENTS (VIA THE ANNUAL REPORT) ARE POSTED ON THE INSTITUTE'S WEBSITE. |
| FORM 990, PART IX, LINE 11G | RESEARCH SUPPORT SERVICES: PROGRAM SERVICE EXPENSES 1,404,700. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,404,700. CONSULTING: PROGRAM SERVICE EXPENSES 836,851. MANAGEMENT AND GENERAL EXPENSES 68,397. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 905,248. OTHER PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 118,245. MANAGEMENT AND GENERAL EXPENSES 7,976. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 126,221. |
Schedule R IRS990ScheduleR
Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (3 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | EINEIN | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile StateLegalDomicileStateCd | Exempt Code SectionExemptCodeSectionTxt | Public Charity StatusPublicCharityStatusTxt | Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt | Controlled OrganizationControlledOrganizationInd | Address Line1ForeignAddress/AddressLine1Txt | CityForeignAddress/CityNm | CountryForeignAddress/CountryCd | Foreign PostalForeignAddress/ForeignPostalCd | Legal Domicile Foreign CountryLegalDomicileForeignCountryCd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRITICAL PATH FOUNDATION | |||||||||||||||
| 1730 EAST RIVER ROAD SUITE 200 | TUCSON | AZ | 85718 | 204780896 | RAISING AND CONTRIBUTING FUNDS TO CRITICAL PATH INSTITUTE | AZ | 501(C)(3) | LINE 11 | CRITICAL PATH INSTITUTE | Yes (1) | |||||
| CRITICAL PATH GLOBAL LTD | |||||||||||||||
| FACILITATE WORK WITH EUROPEAN MEDICINES AGENCY | CRITICAL PATH INSTITUTE | Yes (1) | 20-22 BEDFORD ROW | LONDON | UK | WC1R 4JS | UK | ||||||||
| CRITICAL PATH INSTITUTE LTD | |||||||||||||||
| FACILITATE WORK WITH EUROPEAN MEDICINES AGENCY | CRITICAL PATH INSTITUTE | Yes (1) | 33 SIR JOHN ROGERSONS QUAY | DUBLIN | EI | 2 | EI | ||||||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Receipt Of Int Annts Rnts Rylts | 0 | ReceiptOfIntAnntsRntsRyltsInd |
| Gift Grnt Or Cap Contri To Oth Org | 0 | GiftGrntOrCapContriToOthOrgInd |
| Gift Grnt Cap Contri From Oth Org | 0 | GiftGrntCapContriFromOthOrgInd |
| Loans Or Guarantees To Other Org | 0 | LoansOrGuaranteesToOtherOrgInd |
| Loans Or Guarantees From Oth Org | 0 | LoansOrGuaranteesFromOthOrgInd |
| Div Related Organization | 0 | DivRelatedOrganizationInd |
| Asset Sale To Other Org | 0 | AssetSaleToOtherOrgInd |
| Asset Purchase From Other Org | 0 | AssetPurchaseFromOtherOrgInd |
| Asset Exchange | 0 | AssetExchangeInd |
| Rental Of Facilities To Oth Org | 0 | RentalOfFacilitiesToOthOrgInd |
| Rental Of Fclts From Oth Org | 0 | RentalOfFcltsFromOthOrgInd |
| Perform Of Services For Oth Org | 0 | PerformOfServicesForOthOrgInd |
| Perform Of Services By Other Org | 0 | PerformOfServicesByOtherOrgInd |
| Sharing Of Facilities | Yes (1) | SharingOfFacilitiesInd |
| Paid Employees Sharing | Yes (1) | PaidEmployeesSharingInd |
| Reimbursement Paid To Other Org | 0 | ReimbursementPaidToOtherOrgInd |
| Reimbursement Paid By Other Org | 0 | ReimbursementPaidByOtherOrgInd |
| Transfer To Other Org | 0 | TransferToOtherOrgInd |
| Transfer From Other Org | 0 | TransferFromOtherOrgInd |